source
- FDA Grants First Gene-Therapy Approval for Children 2+ with Sickle Cell DiseaseThe U.S. Food and Drug Administration issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged two years and older who have sickle cell disease with recurrent vaso-oc…
- FDA approves Orca Bio's T-cell therapy to lower graft-versus-host disease risk in blood cancer transplantsThe FDA gave its nod to Orca Bio's personalized T-cell therapy, Tregzi, aimed at patients with blood cancers undergoing stem cell transplants. The therapy is designed to cut the chance of chronic…